Montelukast Events

March 31, 2017
Montelukast Session

Repurposing Of The Anti-asthmatic Drug Montelukast For The Treatment Of Alzheimer’s Disease,
13 International Conference on Alzheimer’s Parkinson’s Diseases
More Information
Scientific Program



Montelukast (INT0043) is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment, alzheimers disease or dementia. The goal is to develop a montelukast oral film product based on the VersaFilm™ proprietary thin film technology by using an already FDA approved drug (Singulair) that has demonstrated potential for the treatment of degenerative diseases of the brain. IntelGenx is currently undergoing a Phase 1 trial and is looking for a partnership or alliance opportunity to complete the development and commercialize Montelukast.

Montelukast (trade name Singulair) is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

The “Mont” in Montelukast stands for Montreal, the place where Merck developed the drug.

IntelGenx Announces Successful Clinical Study for Montekulast for the Treatment of Degenerative Diseases of the Brain

More Information

Researchers are discovering the first approach to healing Alzheimer's

Montekulast and Rejuvenation of the Aged Brain